{"id":"W3217436200","doi":"10.1182/blood-2021-150519","title":"Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA) Targeted CD3-Engaging Bispecific Molecule, for Patients with Relapsed or Refractory Multiple Myeloma: Results from Magnetismm-1","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Institute of Cancer Research; University of Calgary; McGill University Health Centre","funders":"","keywords":"Medicine; Multiple myeloma; Cytokine release syndrome; Lenalidomide; Adverse effect; Common Terminology Criteria for Adverse Events; Neutropenia; Internal medicine; Pomalidomide; Oncology; Febrile neutropenia; Toxicity; Pharmacology; Gastroenterology; Immunotherapy; Cancer; Chimeric antigen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001215746,0.0007794474,0.0009301499,0.0002817728,0.0003343357,0.0006129061,0.0005165226,0.0006372271,0.002819597],"category_scores_gemma":[0.000387849,0.0002501891,0.0008409486,0.0003197165,0.0003374995,0.0004184848,0.0002924847,0.002349666,0.0006491672],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009067523,"about_ca_system_score_gemma":0.001167898,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001185051,"about_ca_topic_score_gemma":0.002334663,"domain_scores_codex":[0.9996277,0.0001409717,0.00002505232,0.00006676295,0.00006245798,0.00007707407],"domain_scores_gemma":[0.9996808,0.0000525658,0.00006519118,0.00002947479,0.00003822139,0.0001338031],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2836625,0.0491819,0.014904,0.001428915,0.001551687,0.000572904,0.0004643409,0.004181318,0.2256056,0.0006309452,0.02054303,0.3972728],"study_design_scores_gemma":[0.1739331,0.6524891,0.06680331,0.0001383136,0.001854805,0.001753102,0.00009444939,0.001754455,0.07016442,0.0003622007,0.03058435,0.0000683714],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9821213,0.00657527,0.001020984,0.001029453,0.0001291651,0.00145493,0.003319936,0.0001766562,0.00417227],"genre_scores_gemma":[0.9780425,0.003880244,0.002374371,0.001239857,0.0001681801,0.0009211383,0.008992601,0.00006018009,0.004320961],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002819597,"threshold_uncertainty_score":0.009432495,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.016623479650107,"score_gpt":0.2455051673231636,"score_spread":0.2288816876730566,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}